SCHEMBL2218560

SCHEMBL2218560

CC(C)(C)OC(=O)N1C[C@@H](NC(=O)OCc2ccccc2)C[C@@](C)(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
USP30 Q70CQ3 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
TSHR P16473 1/20 0.43
ENPP2 Q13822 1/20 0.42
ATXN2 Q99700 1/20 0.42
DPP4 P27487 4/20 0.41
DPP7 Q9UHL4 4/20 0.41
RORC P51449 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
ACHE P22303 2/20 0.41
KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28557849 0.92 HSD11B1 (0.46) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL16655287 0.92 PDE4B (0.46) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL21811339 0.87 HSD11B1 (0.44) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL28657815 0.87 DPP4 (0.49) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL29232309 0.85 ALDH1A1 (0.53) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL30143082 0.85 HSD11B1 (0.44) HSD11B1ALDH1A1GAAUSP30CTSL
SCHEMBL27081666 0.83 ENPP2 (0.57) HSD11B1ALDH1A1GAACTSLCTSB
SCHEMBL376380 0.82 ALDH1A1 (0.46) HSD11B1ALDH1A1GAACTSLCTSB
SCHEMBL21110973 0.82 ALDH1A1 (0.46) HSD11B1ALDH1A1GAACTSLCTSB
SCHEMBL30204000 0.82 L3MBTL1 (0.47) HSD11B1ALDH1A1GAACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045436-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-06-02 US disclosed
US-8466282-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-18 US disclosed
US-20120264733-A1 HETEROCYCLIC COMPOUND AND USE THEREOF SCOHIA PHARMA, INC. (JP) 2012-10-18 US disclosed
US-20110178057-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264733-A1 HETEROCYCLIC COMPOUND AND USE THEREOF REN, AGT, ACE HSD11B1 68/4885ALDH1A1 156/4885GAA 825/4885
US-20110178057-A1 HETEROCYCLIC COMPOUND AND USE THEREOF REN, AGT, ACE HSD11B1 76/4885ALDH1A1 286/4885GAA 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.